Editorial

超高額な希少疾患薬

Nature Biotechnology 32, 5 doi: 10.1038/nbt.2912

Orphan drug development is already difficult enough. Demanding manufacturers account for the development costs of individual drugs for reimbursement is misguided.

目次へ戻る

プライバシーマーク制度